Table 2 Primary outcome and composites
Characteristics | IPDMA | Van Vliet | Salim | ||||||
|---|---|---|---|---|---|---|---|---|---|
Nifedipine (n = 392) | Atosiban (n = 380) | OR or MD (95% CI) | Nifedipine (n = 294) | Atosiban (n = 289) | OR or MD (95% CI) | Nifedipine (n = 98) | Atosiban (n = 91) | OR or MD (95% CI) | |
Composite outcomea | 58/364 (16) | 69/359 (19) | 0.76 (0.47–1.2), p = 0.27 | 51/267 (19) | 60/268 (22) | 0.77 (0.12–5.0), p = 0.79 | 7/97 (7.2) | 9 (9.9) | 0.63 (0.017–24), p = 0.81 |
Perinatal death | 14 (3.6) | 7 (1.8) | 2.01 (0.80–5.1), p = 0.14 | 14 (4.8) | 7 (2.4) | 2.01 (0.80–5.1), p = 0.14 | 0 | 0 | – |
Intraventricular hemorrhage | 6/391 (1.5) | 3/379 (0.8) | 1.95 (0.49–7.9), p = 0.35 | 5 (1.7) | 2/288 (0.70) | 2.47 (0.48–13), p = 0.28 | 1/97 (1.0) | 1 (1.1) | 0.94 (0.058–15), p = 0.96 |
Necrotizing enterocolitis | 7 (1.8) | 8/379 (2.1) | 0.84 (0.30–2.4), p = 0.74 | 7 (2.4) | 4/288 (1.4) | 1.73 (0.50–6.0), p = 0.39 | 0 | 4 (4.4) | – |
Respiratory distress syndrome | 37 (10) | 44 (12) | 0.76 (0.090–6.4), p = 0.80 | 32/267 (12) | 41/267 (15) | 0.72 (0.070–7.4), p = 0.79 | 5 (5.1) | 3 (3.3) | 1.39 (0.008–242), p = 0.90 |
Culture-proven sepsis | 27 (6.9) | 27/379 (7.1) | 0.87 (0.058–13), p = 0.92 | 24 (8.2) | 25/288 (8.7) | 0.84 (0.051–14), p = 0.91 | 3 (3.1) | 2 (2.2) | 1.34 (0.00–1566), p = 0.95 |